Puchheim, Germany

Christoph Erkel

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Novartis Ag. Active years: 2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christoph Erkel. Retrieved from https://idiyas.com/inventor/christoph-erkel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Christoph Erkel: Innovator in Antibody Therapies

Introduction

Christoph Erkel is a notable inventor based in Puchheim, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of antibody therapies. His work focuses on innovative solutions that address critical medical needs.

Latest Patents

Christoph Erkel holds a patent for "ENTPD2 antibodies, combination therapies, and methods of using the antibodies and combination therapies." This patent includes antibodies or antigen-binding fragments that specifically bind to ENTPD2, such as human ENTPD2 protein. The invention also encompasses combination therapies that include an anti-human ENTPD2 antibody and at least one additional therapeutic agent, along with methods for utilizing these therapies.

Career Highlights

Erkel is associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to contribute to groundbreaking research and development in the field of antibody therapies. His innovative approach has the potential to enhance treatment options for various medical conditions.

Collaborations

Some of Christoph Erkel's notable coworkers include Michael DiDonato and Anna Galkin. Their collaborative efforts in research and development have further advanced the field of biotechnology and therapeutic solutions.

Conclusion

Christoph Erkel's contributions to antibody therapies exemplify the innovative spirit of modern biotechnology. His patent on ENTPD2 antibodies represents a significant advancement in therapeutic methods, showcasing the potential for improved patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…